Biomea Fusion

BMEA · Nasdaq · United States

Share price · BMEA

$0.53-0.82 (-60.74%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.0M (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BMEA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Oct 2026-15.2%
  2. 20 Oct 2026-12.0%
  3. 14 Oct 2026-33.8%
  4. 25 Sep 2026-11.4%
  5. 23 Sep 2026-15.3%
  6. 24 Aug 2026+16.1%
  7. 17 Apr 2026+14.5%
  8. 7 Apr 2026+25.8%
  9. 26 Mar 2026+12.3%
  10. 16 Mar 2026-8.1%

Share of unusual movement by asset

For each asset, the share of BMEA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Icovamenib
events and moves
7shown from 8 days
BMF-650
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—9%
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—69%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
MeninSmall molecule
Type 2 DiabetesType 1 Diabetes
Phase 1
GLP-1 receptorSmall molecule
Obesity

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
IcovamenibPhase 2Type 2 Diabetes
Est. primary completion 2027-03 · NCT07502495 · CT.gov ↗
What to watch
June 2027 (1)
IcovamenibPhase 2Type 2 Diabetes
Est. primary completion 2027-06 · NCT07502508 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 October 2026Topline resultBMF-650Phase 1 GLP-131 week-4 results of BMF-650
Biomea Fusion · Source ↗
27 April 2026Topline resultIcovamenibPositive 52-week Phase 2 COVALENT-112 results in type 1 diabetes

Financial reports

Quarterly & interim (20)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$8.5M$27M$6.2M-$8.4M operating cash flowreport ↗
View 19 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$9.1M$35M$8.3M-$10M operating cash flowreport ↗
2026-Q1—$9.1M$45M$12M-$12M operating cash flowreport ↗
2025-Q3—$14M$47M$16M-$12M operating cash flowreport ↗
2025-Q2—$17M$57M$21M-$19M operating cash flowreport ↗
2025-Q1—$23M$36M$29M-$26M operating cash flowreport ↗
2024-Q4—$25M$59M$29M-$30M operating cash flowreport ↗
2024-Q3—$27M$88M$33M-$25M operating cash flowreport ↗
2024-Q2—$32M$114M$37M-$33M operating cash flowreport ↗
2024-Q1—$34M$145M$39M-$32M operating cash flowreport ↗
2023-Q4—$31M$177M$35M-$23M operating cash flowreport ↗
2023-Q3—$25M$199M$28M-$24M operating cash flowreport ↗
2023-Q2—$22M$223M$25M-$26M operating cash flowreport ↗
2023-Q1—$24M$87M$29M-$24M operating cash flowreport ↗
2022-Q4—$21M$112M+ $1.1M short-term inv.$25M-$20M operating cash flowreport ↗
2022-Q3—$18M$133M+ $1.1M short-term inv.$23M-$17M operating cash flowreport ↗
2022-Q2—$13M$149M+ $1.1M short-term inv.$17M-$15M operating cash flowreport ↗
2022-Q1$1.1B$11M$157M+ $8.6M short-term inv.$16M-$10.0M operating cash flowreport ↗
2021-Q4—$11M$146M+ $28M short-term inv.$15M-$16M operating cash flowreport ↗
2021-Q3—$7.9M$157M+ $32M short-term inv.$13M-$9.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$62M$56M$15M-$70M operating cash flowreport ↗

Biomea Fusion reported full-year 2025 results with revenue not disclosed. R&D expenses were $61.98M, down 47.5% YoY from $118.09M, while cash, cash equivalents, and restricted cash totaled $56.18M. The company reported a net loss of $61.8M for the year.

The company projected a cash runway into the first quarter of 2027. Clinical highlights include initiation of Phase II trials COVALENT-211 and COVALENT-212 for icovamenib in type 2 diabetes, with 26-week primary endpoint data expected in the fourth quarter of 2026, and completion of the 52-week follow-up from Phase II COVALENT-112 in type 1 diabetes, with data expected in the second quarter of 2026. Enrollment also began for the Phase I GLP-131 trial of BMF-650 in obesity, with initial 28-day weight reduction data anticipated in the second quarter of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$118M$59M$35M-$120M operating cash flowreport ↗
2023-FY—$103M$177M$29M-$97M operating cash flowreport ↗
2022-FY—$63M$112M+ $1.1M short-term inv.$20M-$62M operating cash flowreport ↗
2021-FY—$28M$146M+ $28M short-term inv.$10M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 4 purchases ($197K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-10Averill Julianne · directorAward / grant (derivative)173,711——Form 4
2026-06-10Ray Sumita · directorAward / grant (derivative)196,299——Form 4
2026-06-10AGUIAR ERIC · directorAward / grant (derivative)196,299——Form 4
2026-06-10Faust Elizabeth · directorAward / grant (derivative)196,299——Form 4
2026-04-01Hitchcock Michael J.M. · director, Interim CEOAward / grant (derivative)667,477——Form 4
2026-04-01Erdtmann Rainer M · director, See RemarksAward / grant (derivative)452,512——Form 4
2025-12-11Erdtmann Rainer M · director, See RemarksOpen-market purchase30,000$1.43$43KForm 4
2025-12-02Hitchcock Michael J.M. · director, Interim CEOOpen-market purchase100,000$0.99$99KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 64 reporting institutions held 24.3M shares ($37.1M, 33.5% of shares outstanding).

#InstitutionSharesValue
1FMR LLC8,813,359$13.5M
2VANGUARD CAPITAL MANAGEMENT LLC2,597,300$4.0M
3Aisling Capital Management LP2,048,757$3.1M
4RENAISSANCE TECHNOLOGIES LLC1,312,798$2.0M
5MARSHALL WACE, LLP1,198,551$1.8M
6CITADEL ADVISORS LLC656,817$1.0M
7Mariner, LLC654,578$1.0M
8BlackRock, Inc.641,435$981K
9SUSQUEHANNA INTERNATIONAL GROUP, LLP629,865$964K
10FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A.557,036$852K
11GEODE CAPITAL MANAGEMENT, LLC548,186$839K
12XTX Topco Ltd530,542$812K
13UBS Group AG515,555$789K
14TWO SIGMA INVESTMENTS, LP388,696$595K
15MORGAN STANLEY346,742$531K